M&A 10:52 ET · Sep 4, 2026 ● Checked against the source TARS TARSUS Closes Alkeus Deal, Adding Phase 3 Stargardt Drug Tarsus Pharmaceuticals has completed its acquisition of Alkeus, gaining worldwide rights to oral Stargardt disease candidate gildeuretinol. Andre·2 min read ID: TARS-2026-09-04-1052 TickersTARS M&A DeskM&A PublishedSep 4, 2026 · 10:52 ET AccessPro story MORE FROM THE DESK Sep 11 · 11:23 ETATAIBECKLEY Delisted as 8-K Points to Completed Eli Lilly TakeoverSep 11 · 06:12 ETARC GROUP ACQUISITION I to Merge With Malaysian Lender at $1.09B ValueSep 10 · 12:02 ETFINGERMOTION Signs Binding MOU for 9.9 MW Powered Land Site in AlbertaSep 10 · 08:46 ETIRISH CONTINENTAL GROUP Shareholders Approve Bluefin BidCo Takeover
